Tempus AI Acquires Personalis to Expand MRD Testing and Biopharma Capabilities
Tempus AI plans to acquire Personalis for $16.25 per share, a deal expected to close in late 2026 or early 2027. The acquisition aims to strengthen Tempus' position in minimal residual disease (MRD) testing and expand its biopharma data capabilities.